NXY-059 for acute ischemic stroke: The promise of neuroprotection is finally realized?

Stroke

Volumn 37, Issue 10, 2006, Pages 2651-2652

  Fisher, Marc ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b University of Massachusetts   (United States)

Author keywords

Neuroprotectants

Indexed keywords

DISUFENTON SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR;

BLEEDING DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; ENDOTHELIUM LESION; HEMISPHERE; HUMAN; NEUROPROTECTION; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANKIN SCALE; RISK; SHORT SURVEY; STATISTICAL SIGNIFICANCE;

BENZENESULFONATES; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; HEMORRHAGE; HUMANS; NEUROPROTECTIVE AGENTS; NITROGEN OXIDES; RANDOMIZED CONTROLLED TRIALS; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33749018199     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000242800.29490.a1     Document Type: Short Survey

References (4)

1. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: Two decades of success and failure. NeuroRx. 2004;1:36-45.
2. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61:1066-1070.
3. Fisher M, Tatlisumak T. Use of animals models has not contributed to development of acute stroke therapies: contra. Stroke. 2005;36:2324-2325.
4. van Swietan JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.